Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate

Bioconjugate Chemistry

Volumn 22, Issue 4, 2011, Pages 540-545

  Harmsen, Stefan ^a   Dolman, M Emmy M ^a   Nemes, Zoltan ^a   Lacombe, Marie ^b   Szokol, Bálint ^c   Pató, János ^c   Kéri, György ^c,d   Öfi, László ^c   Storm, Gert ^a   Hennink, Wim E ^a   Kok, Robbert J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Kreatech Biotechnology BV   (Netherlands)

^c Vichem Chemie Ltd   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; COORDINATION REACTIONS; CYTOLOGY; DRUG THERAPY; ENZYME INHIBITION; METABOLITES; PLATINUM COMPOUNDS;

ANTICANCER DRUG; BIOCONJUGATES; BLOCKINGS; DRUG-RESISTANCE; KINASE INHIBITORS; LONG-TERM SAFETY; NEW APPROACHES; SAFETY RISKS; SALVAGE PATHWAY; SIGNALING CASCADES;

BIOMOLECULES;

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; COORDINATION COMPOUND; CYCLIN DEPENDENT KINASE 2; EPHRIN A7; INDETANIB; MEMBRANE PROTEIN; MULTIKINASE INHIBITOR; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATINUM(II) KINASE INHIBITOR; PROTEIN KINASE FES; PROTEIN TYROSINE KINASE INHIBITOR; RAS P21 PROTEIN ACTIVATOR; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTERIOSCLEROSIS; ARTICLE; CELL DIFFERENTIATION; CELL LYSATE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SELECTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DESIGN; DRUG SAFETY; DRUG STRUCTURE; DRUG UPTAKE; FIBROSIS; FOCAL ADHESION; HUMAN; HUMAN CELL; IC 50; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; TARGET CELL;

EID: 79955012078     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc1005637     Document Type: Article

References (25)

1. Tugues, S., Fernandez-Varo, G., Munoz-Luque, J., Ros, J., Arroyo, V., Rodes, J., Friedman, S. L., Carmeliet, P., Jimenez, W., and Morales-Ruiz, M. (2007) Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats Hepatology 46, 1919-1926
2. Huang, M., Liu, X., Du, Q., Yao, X., and Yin, K. S. (2009) Inhibitory effects of sunitinib on ovalbumin-induced chronic experimental asthma in mice Chin. Med. J. (Engl.) 122, 1061-1066
3. Antoniu, S. A. and Kolb, M. R. (2010) Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis IDrugs 13, 332-345
4. Hartmann, J. T., Haap, M., Kopp, H. G., and Lipp, H. P. (2009) Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects Curr. Drug Metab. 10, 470-481
5. Mego, M., Reckova, M., Obertova, J., Sycova-Mila, Z., Brozmanova, K., and Mardiak, J. (2007) Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma Ann. Oncol. 18, 1906-1907 (Pubitemid 350111579)
6. George, S. (2007) Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor Curr. Oncol. Rep. 9, 323-327 (Pubitemid 47045167)
7. Dolman, M. E., Harmsen, S., Storm, G., Hennink, W. E., and Kok, R. J. (2010) Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells Adv. Drug Delivery Rev. 62, 1344-1357
8. Gajiwala, K. S., Wu, J. C., Christensen, J., Deshmukh, G. D., Diehl, W., DiNitto, J. P., English, J. M., Greig, M. J., He, Y. A., Jacques, S. L., Lunney, E. A., McTigue, M., Molina, D., Quenzer, T., Wells, P. A., Yu, X., Zhang, Y., Zou, A., Emmett, M. R., Marshall, A. G., Zhang, H. M., and Demetri, G. D. (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc. Natl. Acad. Sci. U.S.A. 106, 1542-1547
9. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., and Schlessinger, J. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors Science 276, 955-960 (Pubitemid 27209095)
10. Sun, L., Liang, C., Shirazian, S., Zhou, Y., Miller, T., Cui, J., Fukuda, J. Y., Chu, J. Y., Nematalla, A., Wang, X., Chen, H., Sistla, A., Luu, T. C., Tang, F., Wei, J., and Tang, C. (2003) Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3 Z)-ylidenemethyl]-2,4-dimethyl-1 H -pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J. Med. Chem. 46, 1116-1119 (Pubitemid 36428215)
11. Fretz, M. M., Dolman, M. E., Lacombe, M., Prakash, J., Nguyen, T. Q., Goldschmeding, R., Pato, J., Storm, G., Hennink, W. E., and Kok, R. J. (2008) Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors J. Controlled Release 132, 200-207
12. Hilhorst, R., Houkes, L., van den Berg, A., and Ruijtenbeek, R. (2009) Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A Anal. Biochem. 387, 150-161
13. Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., Heckel, A., and Rettig, W. J. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res. 68, 4774-4782
14. Laird, A. D., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., Fong, T. A., Strawn, L. M., Sun, L., Tang, C., Hawtin, R., Tang, F., Shenoy, N., Hirth, K. P., McMahon, G., and Cherrington (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Res. 60, 4152-4160 (Pubitemid 30636598)
15. Mendel, D. B., Laird, A. D., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R. E., Abrams, T. J., Ngai, T. J., Lee, L. B., Murray, L. J., Carver, J., Chan, E., Moss, K. G., Haznedar, J. O., Sukbuntherng, J., Blake, R. A., Sun, L., Tang, C., Miller, T., Shirazian, S., McMahon, G., and Cherrington, J. M. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin. Cancer Res. 9, 327-337 (Pubitemid 36109749)
16. Prakash, J., Sandovici, M., Saluja, V., Lacombe, M., Schaapveld, R. Q., de Borst, M. H., van Goor, H., Henning, R. H., Proost, J. H., Moolenaar, F., Keri, G., Meijer, D. K., Poelstra, K., and Kok, R. J. (2006) Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1 H -imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis J. Pharmacol. Exp. Ther. 319, 8-19 (Pubitemid 44455106)
17. Moreno, M., Gonzalo, T., Kok, R. J., Sancho-Bru, P., van Beuge, M., Swart, J., Prakash, J., Temming, K., Fondevila, C., Beljaars, L., Lacombe, M., van der Hoeven, P., Arroyo, V., Poelstra, K., Brenner, D. A., Gines, P., and Bataller, R. (2010) Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats Hepatology 51, 942-952
18. Williams, D. S., Carroll, P. J., and Meggers, E. (2007) Platinum complex as a nanomolar protein kinase inhibitor Inorg. Chem. 46, 2944-2946
19. Zhang, L., Carroll, P., and Meggers, E. (2004) Ruthenium complexes as protein kinase inhibitors Org. Lett. 6, 521-523 (Pubitemid 38253273)
20. Maksimoska, J., Williams, D. S., Atilla-Gokcumen, G. E., Smalley, K. S., Carroll, P. J., Webster, R. D., Filippakopoulos, P., Knapp, S., Herlyn, M., and Meggers, E. (2008) Similar biological activities of two isostructural ruthenium and osmium complexes Chemistry 14, 4816-4822
21. Wilbuer, A., Vlecken, D. H., Schmitz, D. J., Kraling, K., Harms, K., Bagowski, C. P., and Meggers, E. (2010) Iridium complex with antiangiogenic properties Angew. Chem., Int. Ed. 49, 3839-3842
22. Spencer, J., Mendham, A. P., Kotha, A. K., Richardson, S. C., Hillard, E. A., Jaouen, G., Male, L., and Hursthouse, M. B. (2009) Structural and biological investigation of ferrocene-substituted 3-methylidene-1,3-dihydro-2 H -indol-2-ones Dalton Trans. 14, 918-921
23. Gasser, G., Ott, I., and Metzler-Nolte, N. (2011) Organometallic anticancer compounds J. Med. Chem. 54, 3-25
24. Chavain, N. and Biot, C. (2010) Organometallic complexes: new tools for chemotherapy Curr. Med. Chem. 17, 2729-2745
25. Hillard, E. A. and Jaouen, G. (2011) Bioorganometallics: future trends in drug discovery, analytical chemistry, and catalysis Organometallics 30, 20-27